8.1 5.9
General Disorders and Administration Site Conditions
Chills 4.8 2.0
Edema 6.5 0.0
Malaise 3.2 0.0
Pyrexia 4.8 2.0
Infections and Infestations
Influenza 4.8 3.9
Pneumonia 4.8 0.0
Sepsis 4.8 2.0
Musculoskeletal and Connective Tissue Disorders
Arthralgia 4.8 3.9
A patient who reported the same medical term more than once was counted only once for that medical term.
Safety parameters (changes in mean Ca, P, Ca × P) in an open-label safety study up to 13 months in duration support the long-term safety of Zemplar in this patient population (see CLINICAL STUDIES).
Other Adverse Reactions Observed During Clinical eva luation of Zemplar Injection
The following adverse reactions, with a causal relationship to Zemplar, occurred in <2% of the Zemplar treated patients in the above double-blind, placebo-controlled clinical trial data set. In addition, the following also includes adverse reactions reported in Zemplar-treated patients who participated in other studies (non placebo-controlled), including double-blind, active-controlled and open-label studies:
Blood and Lymphatic System Disorders:
Anemia, lymphadenopathy
Cardiac Disorders:
Arrhythmia, atrial flutter, cardiac arrest
Ear and Labyrinth Disorders:
Ear discomfort
Endocrine Disorders:
Hyperparathyroidism, hypoparathyroidism
Eye Disorders:
Conjunctivitis, glaucoma, ocular hyperemia
Gastrointestinal Disorders:
Abdominal discomfort, constipation, diarrhea, dysphagia, gastritis, intestinal ischemia, rectal hemorrhage
General Disorders and Administration Site Conditions:
Asthenia, chest discomfort, chest pain, condition aggravated, edema peripheral, fatigue, feeling abnormal, gait disturbance, injection site extravasation, injection site pain, pain, swelling, thirst
Infections and Infestations:
Nasopharyngitis, upper respiratory tract infection, vaginal infection
Investigations:
Aspartate aminotransferase increased, bleeding time prolonged, heart rate irregular, laboratory test abnormal, weight decreased
Metabolism and Nutrition Disorders:
Decreased appetite, hypercalcemia, hyperkalemia, hyperphosphatemia, hypocalcemia
Musculoskeletal and Connective Tissue Disorders:
Joint stiffness, muscle twitching, myalgia
Neoplasms Benign, Malignant and Unspecified:
Breast cancer
Nervous System Disorders:
Cerebrovascular accident, dizziness, dysgeusia, headache, hypoesthesia, myoclonus, paresthesia, syncope, unresponsive to stimuli
Psychiatric Disorders:
Agitation, confusional state, delirium, insomnia, nervousness, restlessness
Reproductive System and Breast Disorders:
Breast pain, erectile dysfunction
Respiratory, Thoracic and Mediastinal Disorders:
Cough, dyspnea, orthopnea, pulmonary edema, wheezing
Skin and Subcutaneous Tissue Disorders:
Alopecia, blister, hirsutism, night sweats, rash pruritic, pruritus, skin burning sensation
Vascular Disorders:
Hypertension, hypotension
Additional Adv